Replies to post #300151 on NorthWest Biotherapeutics Inc (NWBO)

[marzan]

I did. I commented the following there. Hope she fix it.

Leah and Peter, thanks for your positive comment on DcVaxL using the data from the 2018 JTM paper by NWBio but at the same time sorry to say this that the two citations 7 and 14 you used to claim potential patient selection bias do not have anything in the articles to support your assertion. Can you correct it please. Also can you please do a more thorough review and include in your article the following 2018 SNO link that NWBio has in their site that reports an 18 month increase in the mOS from the 2017 data your article considered. By the way the DcVaxL Phase 3 trial is expected to be unblinded in a month in September 2020 where the OS is expected to be even higher around 60 months for 100+ patients. Thanks!

https://www.prnewswire.com/news-releases/updated-interim-data-from-phase-3-trial-of-dcvax-l-for-glioblastoma-presented-at-society-for-neuro-oncology-conference-300752912.html